The treatment of tuberculosis

Disease-a-Month

Volumn 43, Issue 4, 1997, Pages 247-274

  Dutt, Asim K ^a   Stead, William ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANSAMYCIN DERIVATIVE; AZITHROMYCIN; BACTERICIDE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PREDNISONE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ARTICLE; BLOOD TOXICITY; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEUROTOXICITY; PATIENT MONITORING; RASH; TUBERCULOSIS;

EID: 0030892458     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(97)90023-7     Document Type: Article

References (136)

1. Waksman SA, Bugie E, Schatz A. Isolation of antibiotic substance from soil microorganisms with special reference to streptothricin and streptomycin. Mayo Clinic Proc 1944;19:537-48.
2. Schatz A, Waksman SA. Effect of streptomycin and other substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Br Med 1944;57:244-8.
3. Steenken W Jr, Wolinsky E. Antituberculosis properties of hydrazines of isonicotinic acid (Rimifon, Marzalid). Am Rev Tuberc 1952;65:365-75.
4. British Medical Research Council. Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council Investigation. Br Med J 1948;2:769-82.
5. British Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid: a Medical Research Council Investigation. Br Med J 1950;2:1073-85.
6. British Medical Research Council. Treatment of pulmonary tuberculosis with isoniazid: an interim report to Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1952;2:735-46.
7. Mitchison DA. Chemotherapy of tuberculosis: a bacteriologist's viewpoint. Br Med J 1965;5446:1333-40.
8. Riley LW. Drug resistant tuberculosis. Clin Infect Dis 1993;17:442-6.
9. Arachi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72:1-6.
10. Tuberculosis Chemotherapy Trial Committee. Interim report to the Medical Research Council: the treatment of pulmonary tuberculosis with isoniazid. Br Med J 1952;2:735-46.
11. Newman R, Doster B, Murray FJ, Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. Am Rev Respir Dis 1971;103:461-76.
12. Dutt AK, Jones L, Stead WW. Results of short course chemotherapy for tuberculosis with twice weekly isoniazid-rifampin. Chest 1979;75:441-7.
13. British Thoracic and Tuberculosis Association. Short course chemotherapy in pulmonary tuberculosis: a controlled trial. Lancet 1976;2:1102-4.
14. Fox W. The chemotherapy of pulmonary tuberculosis: a review. Chest 1979;76(suppl.):785-96.
15. Grosset J. Bacteriologic basis of short course chemotherapy for tuberculosis. Clin Chest Med 1980;1:231-41.
16. Fox W. The John Barnwell Lecture: changing concepts in the chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1968;97:767-90.
17. Canneti G. The J. Burns Amberson Lecture: present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965;92:687-703.
18. David HL. Drug resistance to M. tuberculosis and other mycobacteria. Clin Chest Med 1980;11:227-30.
19. Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:591-3.
20. Zhang Y, Garbe T, Young D. Transformation with Kat G restores isoniazid-sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentration. Mol Microbiol 1993;8:521-4.
21. Altamirano M, Marostenmaki J, Wong A, et al. Mutations in catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. J Infect Dis 1994;169:1162-5.
22. Stoeckle MY, Guan L, Riegler N, et al. Catalase-peroxidase gene sequences in isoniazid sensitive and resistant strains of Mycobacterium tuberculosis from New York City. J Infect Dis 1993;168:1063-5.
23. Banerjee A, Dubnau E, Quemard A, et al. Inh A, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
24. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampin resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
25. Douglas J, Steyn LM. A ribosomal gene mutation in streptomycin resistant Mycobacterium tuberculosis isolates. J Infect Dis 1993;167:1505-6.
26. Nair J, Rouse D, Bai J, Morris S. Genetic analysis of streptomycin resistance in single and multiple drug resistant strains of Mycobacterium tuberculosis. 93rd Annual Meeting of American Society for Microbiology, Atlanta, Ga., 1993; Abstract U-13.
27. Mitchison DA, Dickinson JM. Bactericidal mechanism in short course chemotherapy of tuberculosis. Bull Int Union Tuberc 1978;53:270-5.
28. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 1978;59:287-97.
29. Fox W. Whither short course chemotherapy? Br J Dis Chest 1981;75:331-57.
30. Mackaness GB, Smith N. The bactericidal action of isoniazid, streptomycin, and terramycin in extracellular and intracellular bacilli. Am Rev Respir Dis 1953;67: 322-40.
31. Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 1977;116:627-35.
32. Clini V, Grassi C. The action of new antituberculosis drugs on intracellular bacilli. Antibiot Chemother 1970;16:20-6.
33. Dickinson JM, Mitchison, DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123:367-71.
34. Mackaness GB. The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc 1950;74:718-21.
35. Dutt AK, Stead WW. Medical perspective: present chemotherapy for tuberculosis. J Infect Dis 1982;146:698-704.
36. Fox W. The current status of short course chemotherapy. Tubercle 1979;60:177-90.
37. Snider DE Jr, Canthen GM, Farer LS, et al. Drug resistant tuberculosis (letter). Am Rev Respir Dis 1991;144:732.
38. Carpenter JL, Obnibene AJ, Gorby EW, et al. Antituberculosis drug resistance in South Texas. Am Rev Respir Dis 1983;128:1055-8.
39. Chawla PK, Klapper PJ, Kamholz SL, et al. Drug resistant tuberculosis in an urban population including patients at risk of human immunodeficiency virus infection. Am Rev Respir Dis 1992;146:280-4.
40. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug resistant tuberculosis in New York City. N Engl J Med 1993;328:521-6.
41. Snider DE Jr, Caras GJ, Koplan JP. Drug resistant tuberculosis in a Southern California Hospital: trends from 1969-1986. Am Rev Respir Dis 1987;135:1307-10.
42. Centers for Disease Control and Prevention. Expanded tuberculosis surveillance and morbidity - United States 1993. MMWR 1994;43:361-6.
43. Ben-Dov I, Mason GR. Drug resistant tuberculosis in a Southern California Hospital: trends from 1969-1986. Am Rev Respir Dis 1987;135:1307-10.
44. Mitchison DA. Drug resistance in mycobacteria. Br Med Bull 1984;40:84-90.
45. Grange JM. Drug resistance and tuberculosis elimination. Bull Int Union Tuberc Lung Dis 1990;65:57-9.
46. Hong Kong Tuberculosis Treatment Service and East African and British Medical Research Council. First-line chemotherapy in the re-treatment of bacteriological relapses of pulmonary tuberculosis following a short course regimen. Lancet 1976;1:162-3.
47. Barnes PF. The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis 1987;136:325-8.
48. Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug resistant Mycobacterium tuberculosis: a community-based study. Am Rev Respir Dis 1989;139:1282-5.
49. Block AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug resistant tuberculosis in the United States. JAMA 1994;271:665-71.
50. Centers for Disease Control. Tuberculosis morbidity - United States 1995. MMWR 1996;45:18, 365-70.
51. Centers for Disease Control. Drug resistance among Indochinese refugees with tuberculosis. MMWR 1981;30:273-5.
52. Reves R, Blakely D, Snider DE Jr, et al. Transmission of multiple drug-resistant tuberculosis : report of a school and community outbreak. Am J Epidemiol 1981;113: 423-5.
53. Snider DE, Kelly GD, Cauthen GM, et al. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985;132:125-32.
54. Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV infected persons. Florida and New York 1988-1991. MMWR 1991;40:585-91.
55. Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and health-care workers. Ann Intern Med 1992;117:191-6.
56. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multidrug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-83.
57. Edlin BR, Tokars JI, Greico MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
58. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV infected patients. JAMA 1992;268:1280-6.
59. Centers for Disease Control. Nosocomial transmission of multidrug-resistant TB to health-care workers and HIV-infected patients in an urban hospital: Florida. MMWR 1990;39:718-22.
60. Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system: New York 1991. MMWR 1992;41:507-9.
61. Dooley SW, Jarvis WR, Martone WJ, et al. Multidrug-resistant tuberculosis (editorial). Ann Intern Med 1992;117:257-9.
62. Centers for Disease Control. Drug resistant tuberculosis among the homeless: Boston. MMWR 1985;34:429-31.
63. Nardell E, McInnis B, Thomas B, et al. Exogenous reinfection with tuberculosis in a shelter for homeless. N Engl J Med 1986;315:1570-5.
64. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44.
65. Stead WW. Management of health care workers after exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med 1995;122:906-12.
66. Dutt AK, Stead WW. Chemotherapy of tuberculosis for the 1980's. Clin Chest Med 1980;1:2, 243-52.
67. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329: 784-91.
68. Stead WW, Dutt AK. Chemotherapy for tuberculosis today. Am Rev Respir Dis 1982;125:94-101.
69. Mitchison DA, Nunn AJ. Influence of initial drug resistance in the response to shortcourse chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133: 423-30.
70. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986;134:355-63.
71. Dutt AK, Moers D, Stead WW. Short course chemotherapy for tuberculosis with mainly twice weekly isoniazid and rifampin: community physicians' seven years experience with mainly outpatients. Am J Med 1984;77:233-42.
72. Dutt AK, Moers D, Stead WW. Short course chemotherapy for extrapulmonary tuberculosis: nine years' experience. Ann Intern Med 1986;104:7-12.
73. Abernathy RS, Dutt AK, Stead WW, et al. Short course chemotherapy for tuberculosis in children. Pediatrics 1983;12:801-6.
74. Snider DE Jr, Zierski M, Graczyk J, et al. Short-course tuberculosis chemotherapy studies conducted in Poland during the past decade. Eur J Respir Dis 1986;68:12-8.
75. Centers for Disease Control. Initial therapy for tuberculosis in the era of multi-drug resistance: recommendation of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42(RR-7):1-8.
76. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988;94:845-50.
77. Manalo F, Tan F, Sbarbaro JA, Iseman MD. Community based short course treatment of pulmonary tuberculosis in a developing nation. Am Rev Respir Dis 1990;142: 1301-5.
78. Girling DJ. The chemotherapy of tuberculosis. Biol Mycobacteria 1989;3:285-94.
79. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-11.
80. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
81. Iseman MD, Madsen LA. Drug resistant tuberculosis. Clin Chest Med 1989;10:341-53.
82. Goble M. Drug resistant tuberculosis. Semin Respir Infect 1986;1:270-9.
83. Stead WW, Young C, Hartnett C. Probable role of ultraviolet irradiation in preventing transmission of tuberculosis: a case study. Infect Control Hosp Epidemiol 1996;17:11-3.
84. Maloney SA, Pearson ML, Gordon TM, et al. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health-care workers. Ann Intern Med 1995;120:90-5.
85. Iseman MD. Treatment of multidrug-resistant tuberculosis (Erratum). N Engl J Med 1993;329:1435.
86. Iseman MD, Madsen L, Goble M, et al. Surgical intervention in the treatment of pulmonary disease caused by drug resistant Mycobacterium tuberculosis. Am Rev Respir Dis 1990;141:623-5.
87. Stead WW, To T, Harrison RW, et al. Benefit-risk consideration in preventive treatment for tuberculosis in elderly persons exposed to multi-drug resistant tuberculosis. MMWR 1992; 40(RR-11):61-74.
88. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five year follow-up in the IUAT trial. Bull WHO 1982;60:555-64.
89. Koplan JP, Farer LS. Choice of preventive treatment for isoniazid-resistant tuberculosis infection: use of decision analysis and the Delphi technique. JAMA 1980;244: 2736-40.
90. Centers for Disease Control. Management of persons exposed to multi-drug resistant tuberculosis. MMWR 1992;40 (RR-11):61-71.
91. Small PM, Schecter GF, Goodman PC, et al. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324: 289-94.
92. Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994;150:1499-502.
93. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised intermittent therapy for tuberculosis in HIV infected patients. AIDS 1994;8:1103-8.
94. Fischl MA, Daikos GL, Uttamchandani RD, et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple drug resistant bacilli. Ann Intern Med 1992;117:184-90.
95. Anonymous. Smear negative pulmonary tuberculosis. Tubercle 1980;61:113-5.
96. Narain R, Nair SS, Naganna K, et al. Problem of defining a case of pulmonary tuberculosis in prevalence survey. Bull WHO 1968;39:701-29.
97. Dutt AK, Stead WW. Smear negative pulmonary tuberculosis. Semin Respir Infect 994;9:2:113-9.
98. Singapore Tuberculosis Service/British Medical Research Council. Long term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:779-83.
99. Hong Kong Chest Service/Tuberculosis Research Center Madras/British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum smear negative pulmonary tuberculosis: results at 5 years. Am Rev Respir Dis 1989;139:871-6.
100. American Thoracic Society/Centers for Disease Control. Recommendations for the treatment and preventive treatment of tuberculosis. Am J Respir Crit Care Med 1994;151:1359-74.
101. DuttAK, Moers D, Stead WW. Smear-negative culture-positive pulmonary tuberculosis: six month chemotherapy with isoniazid and rifampin. Am Rev Respir Dis 1990;144:1232-5.
102. Dutt AK, Moers D, Stead WW. Tuberculous pleural effusion: six month therapy with isoniazid and rifampin. Am Rev Respir Dis 1992;145:1429-32.
103. Omerod LP, McCarthy OR, Rudd RM, et al. Short course chemotherapy for tuberculosis pleural effusion and culture negative pulmonary tuberculosis. Tubercle Lung Dis 1995;76:25-7.
104. Dutt AK, Moers D, Stead WW. Smear negative and culture negative pulmonary tuberculosis: four months short course chemotherapy. Am Rev Respir Dis 1989;139:867-70.
105. American Thoracic Society/Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986;134: 355-63.
106. Dutt AK, Moers D, Stead WW. Short course chemotherapy for extrapulmonary tuberculosis: nine years' experience. Ann Intern Med 1986;104:7-12.
107. Starke JR. Multidrug therapy for tuberculosis in children. Pediatr Infect Dis J 1990;9: 785-93.
108. Report of the Committee in Infectious Disease, 22nd ed. Elk Grove, IL. American Academy of Pediatrics 1991:487.
109. Snider DE, Jr, Layde PM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis 1980;122:65-79.
110. Snider DE, Jr., Powell KE. Should women taking antituberculosis drugs breast feed? Arch Intern Med 1984;144:589-90.
111. Hamdeh MA, Glassroth J. Tuberculosis and pregnancy. Chest 1992;101:1114-20.
112. Andrew OT, Schonfield PY, Hopewell PC, et al. Tuberculosis in patients with endstage renal disease. Am J Med 1980;68:59-65.
113. Cross FS, Long MW, Banner AS, et al. Rifampin-isoniazid therapy of alcoholic and non-alcoholic tuberculosis patients in a U.S. public health service cooperative therapy trial. Am Rev Respir Dis 1980;122:349-53.
114. Dautzenburg B, Grosset J, Fechner J, et al. The management of thirty immunocompromised patients with tuberculosis. Am Rev Respir Dis 1984;129:494-6.
115. Davidson PT, Le HQ. Drug treatment of tuberculosis-1992. Drugs 1992;43:651-73.
116. Muthuswamy P, Tzyy-Chyn H, Carasso B, et al. Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Chest 1995;107:1621-30.
117. Masud T, Kemp E. Corticosteroids in treatment of disseminated tuberculosis in a patient with HIV infection. Br Med J 1988;296:464-5.
118. Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone adjunctive treatment for tuberculosis meningitis. Pediatr Infect Dis J 1991;10:179-83.
119. Lee CH, Wang WJ, Lan RS, et al. Corticosteroid in the treatment of tuberculous pleurisy: a double-blind, placebo controlled randomized study. Chest 1988;94:1256-9.
120. Wyser C, Walzi G, Smedema JP, et al. Corticosteroids in the treatment of tuberculous pleurisy: a double blind, placebo controlled, randomized study. Chest 1996;110:333-8.
121. Fowler NO. Tuberculous pericarditis. JAMA 1991;266:99-103.
122. Strang JI, Kakaza HH, Gibson DG, et al. Controlled trial of prednisone adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987;2:418-22.
123. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness and the decline of tuberculosis programs. Am Rev Respir Dis 1991;144:745-9.
124. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993;270:65-8.
125. Brudney K, Dobkin J. A tale of two cities: tuberculosis in Nicaragua and New York City. Semin Respir Infect 1991;6:261-72.
126. Weis SE, Slveum PC, Blais FX, et al. The effect of directly observed therapy on the rate of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
127. Cohn DL, Catlin BJ, Peterson KL, et al. A 62 dose, six month therapy for pulmonary and extrapulmonary tuberculosis: a twice weekly, directly observed and cost effective regimen. Ann Intern Med 1990;112:407-15.
128. Chaisson RE, Clermont HC, Holt EA, et al. Six months supervised intermittent tuberculosis therapy in Haitian patients with or without HIV infection. Am J Repir Crit Care Med 1996;154:1034-8.
129. Moore RD, Chaulk CP, Griffiths R, et al. Cost effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996;154:1013-9.
130. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993;328:576-8.
131. Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medication to prevent drug resistance. Ann Intern Med 1995;122:951-4.
132. Sbarboro J. Tuberculosis: yesterday, today and tomorrow. Ann Intern Med 1995;122: 955-6.
133. Byrd RB, Horn BR, Soloman DA, et al. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: role of biochemical monitoring in 1000 patients. JAMA 1979;241: 1239-41.
134. Bailey WC, Taylor SC, Dascomb WH, et al. Disturbed hepatic function during isoniazid chemoprophylaxis: monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis 1973;107:523-9.
135. Dutt AK, Moers D, Stead WW. Undesirable side effects of isoniazid and rifampin in largely twice weekly short course chemotherapy for tuberculosis. Am Rev Respir Dis 1983;128:419-24.
136. Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1978;59:13-32.